leadf
logo-loader
viewAnteris Technologies Ltd
(
ASX:AVROTC:AMEUFFRA:DDF
)

Anteris Technologies appoints highly experienced chief medical officer

The appointment of Dr Meduri, a recognised leader in the field of valvular heart disease, is expected to give further credibility to Anteris’ DurAVR™ aortic replacement valve.

Anteris Technologies Ltd - Anteris Technologies appoints highly experienced Chief Medical Officer
DurAVR™ is being developed to address acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF, FRA:DDF) has appointed internationally recognised Interventional Cardiologist, Dr Chris Meduri MD MPH, as its chief medical officer (CMO).

Anteris is a structural heart company developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

The appointment of Dr Meduri, a recognised leader in the field of valvular heart disease, is expected to give further credibility to Anteris’ DurAVR™ aortic replacement valve.

DurAVR™ is being developed to address acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

Right time for a CMO

Dr Meduri has served as the national principle investigator of several valve trials and on numerous steering committees and has performed first-in-US and first-in-world procedures, led enrolment in many trials and actively participated in 11 transcatheter early feasibility studies.

“With the rapid progress of the DurAVR™ program, the timing is now right just ahead of our planned early feasibility study to establish the role of CMO,” Anteris’ chief executive officer Wayne Paterson said.  

“Chris has been working as an Advisory Board member, so his transition into the CMO role will be seamless.

"Whilst still maintaining external clinical practice responsibilities, the additional time commitment from him in this new role will help us advance even further whilst adding greater credibility and profile to our product.

"Chris is well known and respected within the global cardiology community. We are thrilled he has agreed to be our CMO.”

Appointment already knows the business

Dr Meduri has been an active member of the Anteris Medical Advisory Board since inception and has already contributed significantly to the current development progress of DurAVR™.

The experience with DurAVR™ and the extra attention Dr Meduri will bring should prove invaluable to Anteris as it continues to fast track its feasibility study.

Dr Meduri’s reputation could also play a role in Anteris’ recognition within the medical community.

He has performed more than 1500 TAVR (Transcatheter aortic valve replacement) procedures using all currently available products, helped to build post-operative care pathways for TAVR patients and developed an app used to optimize the care of TAVR patients.

TAVR procedures replace a diseased aortic valve with a man-made valve.

 “I am honoured to take on a broader role with the Anteris team to help deliver on its mission of delivering the world’s most durable heart valve. I look forward to collaborating with the talented team and advisory board to launch the DurAVR™ product and aid in providing a longer-lasting TAVR future for all patients,” Dr Meduri said.

Dr Meduri is widely published in areas such as TAVR, mitral valve repair and replacement, tricuspid repair and others.

He is also an active speaker and live case operator at numerous major international cardiac and medical conferences.

Meduri completed his general, interventional and structural heart disease training at Beth Israel Deaconess Medical Center, Harvard Medical School and completed his Masters in Public Health (MPH) with a focus on Clinical Effectiveness at the Harvard School of Public Health. He completed his internship and residency in Internal Medicine at Duke University.

Quick facts: Anteris Technologies Ltd

Follow
ASX:AVR

Price: 8.23 AUD

Market Cap: $66.34 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Anteris Technologies 'sitting on a significantly large opportunity' as it...

Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson speaks to Proactive following the company's AGM. It's recently achieved a breakthrough in manufacturing the tissue used in ADAPT® treated products from bovine pericardium, after developing specialised machinery to create consistently thin...

on 15/7/21

3 min read